5th ICHNO Programme Book

Freedom from regional failure of contralateral neck with ipsilateral neck radiothe- rapy for node and tonsil cancer A. Raben (USA), T.U. Dan, C. Schneider, N. Hockstein, R. Witt The pharmacokinetic characteristics of nimorazole in head and neck cancer patients treated in the DAHANCA-5 trial M.A.H. Metwally (Denmark), J.A. Jansen, J. Overgaard Evaluation of the impact of the oral cavity contour on dose and constraint com- pliance in head-and-neck IMRT I. Prieto (Spain), S. Gomez-Tejedor, J.P. Marin, A.M. Perez IMRT in nasopharyngeal carcinoma - Single institution - Experience from a develo- ping country C. Kainickal, B. Azariah (India), R. Kumar, M. Rafi, A. Sudha, R. Rajeev, S. Bhasi, R. Kunnambath Long-term outcome of 18F-FDG-PET-guided dose painting for head and neck cancer: matched case-controlled study D. Berwouts (Belgium), F. Duprez, A.M.L. Olteanu, W. De Gersem, T. Vercauteren, T. Boterberg, P. Deron, K. Bonte, W. De Neve, I. Madani Chemoradiotherapy for poor/intermediate risk oropharyngeal carcinoma: First results of the ArCHIMEDEs study V. Harrop (United Kingdom), S. Meade, L. Wagstaff, J. Babrah, P. Gaunt, M. Robinson, J. Cash more, H. Mehanna, A. Hartley, P. Sanghera Normal tissue complication probability based multicriteria optimised IMRT in head and neck cancer radiotherapy K. Wopken, R.G.J. Kierkels (The Netherlands), H.P. Bijl, J.A.L. Langendijk TPExtreme randomised trial: Docetaxel-Platinum(P)-Cetuximab(C) versus 5FU- P-C in recurrent/metastatic HNSCC J. Guigay (France), U. Keilholz, R. Mesia, N. Vintonenko, J. Bourhis, A. Auperin Phase II study of TPF and cetuximab+RT in locally advanced laryngeal/hypopha- ryngeal carcinoma F. Arias (Spain), I. Hernández, G. Asín, J. Contreras, E. Villar, A.M. Pérez, V. Casado, T. Bonfill, R. Vera Adaptive radiotherapy in head and neck cancer Y. Yahsi (Turkey), A. Okumus, T.O. Gursoy, O. Zeybek, H.O. Kizilkaya

PO-083

PO-084

PO-085

PO-086

PO-087

PO-088

PO-089

PO-090

PO-091

PO-092

PROGRAMME & EXHIBITION GUIDE | POSTERS

27